Morgan Stanley Maintains Overweight on Royalty Pharma, Lowers Price Target to $54
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and lowers the price target from $55 to $54.
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and lowers the price target from $55 to $54.